Bayer to present new Stivarga data at ASCO GI 2016

Bayer will be presenting new clinical study data on its cancer drug Stivarga at the 2016 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO GI 2016).

To be held in San Francisco from January 21st to 23rd, the conference will give Bayer the opportunity to share findings from several Stivarga studies, including long-term responder data and additional analyses from its phase III clinical trials programme, which involved more than 3,500 patients with metastatic colorectal cancer.

Additional data will be presented from the final overall survival analysis of Stivarga taken from a large phase III clinical trial among gastrointestinal stromal tumour patients.

Dr Dario Mirski, Bayer's senior vice-president and head of medical affairs, said: "The latest analyses of regorafenib expand our understanding of its clinical use across different tumour types, allowing us to further contribute to growing scientific knowledge that benefits patients worldwide."

Stivarga is indicated for previously-treated metastatic colorectal cancer patients or those with locally advanced, unresectable or metastatic gastrointestinal stromal tumours.

The drug is considered to be one the company's key pillars of growth, alongside Xarelto, Eylea, Xofigo and Adempas.